PT-141 (Bremelanotide) Pharmacokinetics and Pharmacodynamics in Healthy Women
Rosen RC, Diamond DA, Dondiego WE, et al.
Journal of Clinical Pharmacology, 2013 · n = 45
Key finding
Plasma bremelanotide levels peaked at 60 minutes and correlated with genital arousal response (r=0.64, p<0.01).
Summary
Pharmacokinetic study establishing bremelanotide time-to-peak (60 min), half-life (26-42 min), and relationship between plasma levels and sexual response.
Read the study
The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.
View on PubMedRelated compound
More research on PT-141
Comparison of PT-141 and Flibanserin for Female Sexual Desire Disorder: An Indirect Treatment Comparison
Sexual Medicine Reviews · 2022 · Review
Blood Pressure and Cardiovascular Effects of Bremelanotide in Hypertensive Versus Normotensive Women
Journal of Sexual Medicine · 2021 · Human RCT
Long-Term Safety and Efficacy of Bremelanotide: 1-Year Extension Study in Women with HSDD
The Journal of Sexual Medicine · 2021 · Human Pilot
RECONNECT-1: A Randomized Controlled Trial of Bremelanotide for Female Sexual Desire Disorder
The Journal of Sexual Medicine · 2020 · Human RCT
RECONNECT-2: Phase 3 Trial of Bremelanotide in Premenopausal Women with Generalized Hypoactive Sexual Desire Disorder
The Journal of Sexual Medicine · 2020 · Human RCT